The therapeutic effect of IL-21 combined with IFN-γ inducing CD4+CXCR5+CD57+T cells differentiation on hepatocellular carcinoma

Introduction: Liver cancer is a malignant tumor with high incidence and short survival time. In order to increase the cure rate and disease-free survival rate of liver cancer, it is necessary to seek effective treatment methods. Objectives: The objective of this study is to evaluate the therapeutic effects of IL-21 and IFN-gamma inducing the formation of CD4(+)CXCR5(+)CD57(+)T cells on liver cancer. Methods: The methods of analyze the relationship between CD4(+)CXCR5(+)CD57(+)T cells and the survival time of hepatocellular carcinoma (HCC), and study the effect of IL-21 combined with IFN-gamma in inducing stem cells to differentiate into CD4(+)CXCR5(+)CD57(+)T cells. The effects of IL-21 combined with IFN-gamma induced CD4(+)CXCR5(+)CD57(+)T cells on liver cancer were studied through animal experiments, and the regulatory mechanism, and the effect of hepatitis B virus (HBV) on it. Results: The study found that the number of CD4(+)CXCR5(+)CD57(+)T cells in serum of liver cancer patients with prolonged survival time increased significantly, the expression of CD4, CD57, and CXCR5 in the tumor microenvironment increased, and the serum IL-21 and IFN-gamma concentrations increased. IL-21 and IFN-gamma induce stem cells to differentiate into CD4(+)CXCR5(+)CD57(+)T cells and induce HepG2 cells apoptosis. HBV leads to a decrease in the number of CD4(+)CXCR5(+)CD57(+)T cells and a chronic inflammatory response. Treg cells can regulate CD4(+)CXCR5(+)CD57(+)T cells. IL-21 combined with IFN-gamma induced an increase in the number of CD4(+)CXCR5(+)CD57(+)T cells in hepatocarcinoma-bearing mice, which has an inhibitory effect on H22 liver cancer. Conclusion: The conclusion of the study is that IL-21 combined with IFN-gamma induces stem cells to differentiate into CD4(+)CXCR5(+)CD57(+)T cells, Treg can control the increase in their number, and HBV can cause their number to decrease, which can control the growth of liver cancer. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University.